Skip to content
Home
About
Overview
Team Background
Public Healthcare
Team
Leadership
Board of Directors
Scientific Advisory Board
Senior Advisors
Programs
Overview
Pipeline
Strategic Partners
Drug Candidates
CO-sTiRNA™
MRI-1867
Additional R&D Programs
Scientific Publications
Media
News and Events
Press Releases
News
Events
Presentations
Investors
Company Information
News and Events
Presentations
SEC Filings
Corporate Governance
Stock Data
Research Coverage
Contact
Menu
Home
About
Overview
Team Background
Public Healthcare
Team
Leadership
Board of Directors
Scientific Advisory Board
Senior Advisors
Programs
Overview
Pipeline
Strategic Partners
Drug Candidates
CO-sTiRNA™
MRI-1867
Additional R&D Programs
Scientific Publications
Media
News and Events
Press Releases
News
Events
Presentations
Investors
Company Information
News and Events
Presentations
SEC Filings
Corporate Governance
Stock Data
Research Coverage
Contact
Scopus BioPharma - Underwriters Exercise Over-Allotment Option in Full, Brings Total Follow-On Public Offering Proceeds to $10.35 Million (02.08.21) FINAL
×
